Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss

Study Summary

This is a first in human study of TNG456 alone and in combination with abemaciclib in patients with advanced or metastatic solid tumors known to have an MTAP loss. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specific solid tumor types with a confirmed MTAP loss. The study drug, TNG456, is a selective PRMT5 inhibitor administered orally. The study is planned to treat up to 191 participants.

Conditions

Non Small Cell Lung Cancer Glioma Glioblastoma Multiforme Glioma, Malignant Solid Tumor Non-Small Cell Adenocarcinoma Lung Cancer Brain Tumor

Interventions / Drugs

TNG456 abemaciclib

View on ClinicalTrials.gov ↗

Sponsor

TNGX

Tango Therapeutics, Inc.

Biotech / Pharma

D40/100

Study Details

Enrollment191 participants

Primary Completion—

Lead SponsorTango Therapeutics, Inc.

Data Retrieved2026-04-11 04:29:38.262376+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.